Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-15T06:19:15.649Z Has data issue: false hasContentIssue false

Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007

Published online by Cambridge University Press:  02 January 2015

Alicia I. Hidron
Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
Jonathan R. Edwards
Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion, Atlanta, Georgia
Jean Patel
Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion, Atlanta, Georgia
Teresa C. Horan
Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion, Atlanta, Georgia
Dawn M. Sievert*
Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion, Atlanta, Georgia
Daniel A. Pollock
Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion, Atlanta, Georgia
Scott K. Fridkin
Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion, Atlanta, Georgia
Surveillance Branch, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, NE Mailstop A-24, Atlanta, GA 30333 (



To describe the frequency of selected antimicrobial resistance patterns among pathogens causing device-associated and procedure-associated healthcare-associated infections (HAIs) reported by hospitals in the National Healthcare Safety Network (NHSN).


Data are included on HAIs (ie, central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated pneumonia, and surgical site infections) reported to the Patient Safety Component of the NHSN between January 2006 and October 2007. The results of antimicrobial susceptibility testing of up to 3 pathogenic isolates per HAI by a hospital were evaluated to define antimicrobial-resistance in the pathogenic isolates. The pooled mean proportions of pathogenic isolates interpreted as resistant to selected antimicrobial agents were calculated by type of HAI and overall. The incidence rates of specific device-associated infections were calculated for selected antimicrobial-resistant pathogens according to type of patient care area; the variability in the reported rates is described.


Overall, 463 hospitals reported 1 or more HAIs: 412 (89%) were general acute care hospitals, and 309 (67%) had 200-1,000 beds. There were 28,502 HAIs reported among 25,384 patients. The 10 most common pathogens (accounting for 84% of any HAIs) were coagulase-negative staphylococci (15%), Staphylococcus aureus (15%), Enterococcus species (12%), Candida species (11%), Escherichia coli (10%), Pseudomonas aeruginosa (8%), Klebsiella pneumoniae (6%), Enterobacter species (5%), Acinetobacter baumannii (3%), and Klebsiella oxytoca (2%). The pooled mean proportion of pathogenic isolates resistant to antimicrobial agents varied significantly across types of HAI for some pathogen-antimicrobial combinations. As many as 16% of all HAIs were associated with the following multidrug-resistant pathogens: methicillin-resistant S. aureus (8% of HAIs), vancomycin-resistant Enterococcus faecium (4%), carbapenem-resistant P. aeruginosa (2%), extended-spectrum cephalosporin-resistant K. pneumoniae (1%), extended-spectrum cephalosporin-resistant E. coli (0.5%), and carbapenem-resistant A. baumannii, K. pneumoniae, K. oxytoca, and E. coli (0.5%). Nationwide, the majority of units reported no HAIs due to these antimicrobial-resistant pathogens.

NHSN Annual Update
Copyright © The Society for Healthcare Epidemiology of America 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


1.Esposito, S, Leone, S. Antimicrobial treatment for intensive care unit (ICU) infections including the role of the infectious disease specialist. Int J Antimicrob Agents 2007;29:494500.CrossRefGoogle ScholarPubMed
2.Bradley, JS, Guidos, R, Baragona, S, et al.Anti-infective research and development-problems, challenges, and solutions. Lancet Infect Dis 2007;7:6878.CrossRefGoogle ScholarPubMed
3.Huang, SS, Yokoe, DS, Hinrichsen, VL, et al.Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide mefhicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2006;43:971978.CrossRefGoogle ScholarPubMed
4.Schwaber, MJ, Carmeli, Y. Mortality and delay in effective therapy associated with extended-spectrum /3-lactamase production in Enterobac-teriaceae bacteremia: a systematic review and meta-analysis. J Antimicrob Chemother 2007;60:913920.CrossRefGoogle Scholar
5.Chambers, HECommunity-associated MRSA-resistance and virulence converge. N Engl J Med 2005;352:14851487.CrossRefGoogle ScholarPubMed
6.Deshpande, LM, Fritsche, TR, Moet, GJ, Biedenbach, DJ, Jones, RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58:163170.CrossRefGoogle ScholarPubMed
7.Lewis, JS 2nd, Herrera, M, Wiekes, B, Patterson, JE, Jorgensen, JH. First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 2007;51:40154021.CrossRefGoogle Scholar
8.Moland, ES, Hanson, ND, Black, JA, Hossain, A, Song, W, Thomson, KS. Prevalence of newer β-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol 2006;44:33183324.CrossRefGoogle ScholarPubMed
9.Lockhart, SR, Abramson, MA, Beekmann, SE, et al.Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007;45:33523359.CrossRefGoogle ScholarPubMed
10.Edwards, JR, Peterson, KD, Andrus, ML, et al.National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007. Am J Infect Control 2007;35:290301.CrossRefGoogle ScholarPubMed
11.CDC. The National Healthcare Safety Network (NHSN) Manual. Patient Safety Component Protocol. Division of Healthcare Quality Promotion. Available at: Accessed December 12, 2007.Google Scholar
12.CLSI. Performance standards for antimicrobial susceptibility testing: 16th informational supplement. CLSI document. Wayne, PA: CLSI, 2008: M100-S18.Google Scholar
13.CLSI. Analysis and presentation of cumulative antimicrobial susceptibility test data: approved guideline. 2nd ed. Wayne, PA: CLSI, 2006:M39-A2.Google Scholar
14.Bradford, PA, Bratu, S, Urban, C, et al.Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin Infect Dis 2004;39:5560.CrossRefGoogle Scholar
15.CDC. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520532.CrossRefGoogle Scholar
16.CDC. National Nosocomial Infections Surveillance (NNIS) system report, data summary from October 1986-April 1998, issued June 1998. Available at: Accessed at December 12, 2007.Google Scholar
17.Klevens, RM, Edwards, JR, Tenover, FC, McDonald, LC, Horan, T, Gaynes, R; National Nosocomial Infections Surveillance System. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006;42:389391.CrossRefGoogle ScholarPubMed
18.National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470485.CrossRefGoogle Scholar
19.Streit, JM, Jones, RN, Sader, HS, Fritsche, TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24:111118.CrossRefGoogle ScholarPubMed
20.Stephen, JM, Jones, RN. Assessment of pathogens and resistance (R) patterns among intensive care unit (ICU) patients in North America (NA): initial report from the SENTRY Antimicrobial Surveillance Program (2001). In: Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy American Society for Microbiology; September 27-30, 2002; San Diego, CA. Abstract C2-297.Google Scholar
21.Jones, ME, Draghi, DC, Thornsberry, C, Karlowsky, JA, Sahm, DF, Wenzel, RP. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004;3:14.CrossRefGoogle ScholarPubMed
22.Fluit, AC, Verhoef, J, Schmitz, FJ. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. Eur J Clin Microbiol Infect Dis 2001;20:617625.CrossRefGoogle ScholarPubMed
23.Vincent, JL, Bihari, DJ, Suter, PM, et al.The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:639644.CrossRefGoogle Scholar
24.Fridkin, SK, Steward, CD, Edwards, JR, et al.Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999;29:245252.CrossRefGoogle ScholarPubMed
25.Fridkin, SK, Hill, HA, Volkova, NV, et al.Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002;8:697701.CrossRefGoogle ScholarPubMed
26.Diekema, DJ, Pfaller, MA, Jones, RN, et al.Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999;29:595607.Google ScholarPubMed
27.Diekema, DJ, Pfaller, MA, Jones, RN, et al.; SENTRY Participants Group. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. Int J Antimicrob Agents 2000;13:257271.CrossRefGoogle ScholarPubMed
28.Richards, C, Emori, TG, Edwards, J, Fridkin, S, Toison, J, Gaynes, R. Characteristics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999. Am J Infect Control 2001;29:400403.CrossRefGoogle ScholarPubMed